Exchange Traded Concepts LLC Purchases 2,036 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Exchange Traded Concepts LLC grew its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 6.5% in the 3rd quarter, HoldingsChannel reports. The firm owned 33,403 shares of the life sciences company’s stock after acquiring an additional 2,036 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Integra LifeSciences were worth $607,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. State of Michigan Retirement System lifted its position in Integra LifeSciences by 2.5% in the 1st quarter. State of Michigan Retirement System now owns 16,690 shares of the life sciences company’s stock worth $592,000 after buying an additional 400 shares during the last quarter. CWM LLC lifted its holdings in shares of Integra LifeSciences by 50.8% in the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after acquiring an additional 425 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Integra LifeSciences by 100.5% during the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 444 shares during the last quarter. CANADA LIFE ASSURANCE Co raised its position in Integra LifeSciences by 1.1% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 49,762 shares of the life sciences company’s stock worth $1,764,000 after purchasing an additional 551 shares during the period. Finally, Texas Permanent School Fund Corp lifted its stake in Integra LifeSciences by 1.5% in the first quarter. Texas Permanent School Fund Corp now owns 59,524 shares of the life sciences company’s stock worth $2,110,000 after purchasing an additional 870 shares during the last quarter. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Trading Up 0.6 %

Shares of IART opened at $19.87 on Friday. Integra LifeSciences Holdings Co. has a 1-year low of $16.81 and a 1-year high of $45.42. The company has a current ratio of 3.39, a quick ratio of 2.10 and a debt-to-equity ratio of 1.17. The firm’s 50-day moving average price is $19.03 and its 200-day moving average price is $25.57. The firm has a market capitalization of $1.57 billion, a price-to-earnings ratio of 39.74, a PEG ratio of 0.62 and a beta of 1.09.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Monday, July 29th. The life sciences company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.01. The business had revenue of $418.20 million for the quarter, compared to analysts’ expectations of $413.07 million. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. The business’s revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.71 EPS. Sell-side analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. BTIG Research raised Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. JMP Securities lowered their price objective on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research report on Tuesday, July 30th. Truist Financial cut their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, October 14th. Bank of America lowered their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Finally, Morgan Stanley raised their price target on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a report on Monday, July 15th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $26.50.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.